Please login to the form below

Not currently logged in
Email:
Password:

LionsDen Communications Award for Excellence in Payer and Policymaker Engagement

Sponsored by

Finalist

Osteosarcoma – rewriting the rule book

Takeda UK in association with Liberation Communications


Summary of work

Mepact (mifamurtide) is the first advance in osteosarcoma treatment for more than 20 years. A very rare form of bone cancer, osteosarcoma is highly aggressive with a propensity to metastasise, affecting around 150 children and young adults each year across the UK.

Before Mepact a third of all children and young adults diagnosed with osteosarcoma did not survive. With Mepact up to an estimated additional 12 children each year across the UK will survive osteosarcoma and go on to live “normal‟ long lives. 

In July 2010, NICE gave initial guidance, which did not recommend Mepact for use on the NHS in England despite a Patient Access Scheme (PAS) being proposed by Takeda. The SMC also gave a negative decision. 

Takeda worked with the Department of Health, NICE and the SMC to find a solution. After three further appraisal committee meetings, NICE acknowledged that to evaluate the health economic value of Mepact accurately, it would need to change its methodology to assess medicines, which improve survival rates beyond 30 years. 

Following a fifth appraisal committee meeting a positive decision for the use of Mepact was given. The SMC also reversed its initial negative decision to recommend the use of Mepact in Scotland.

 

 

Executive summary as submitted


COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics